Nutrients,
Journal Year:
2024,
Volume and Issue:
16(20), P. 3558 - 3558
Published: Oct. 20, 2024
Alzheimer's
disease
(AD)
is
a
common
clinical
neurodegenerative
disorder,
primarily
characterized
by
progressive
cognitive
decline
and
behavioral
abnormalities.
The
hallmark
pathological
changes
of
AD
include
widespread
neuronal
degeneration,
plaques
formed
the
deposition
amyloid
β-protein
(Aβ),
neurofibrillary
tangles
(NFTs).
With
acceleration
global
aging,
incidence
rising
year
year,
making
it
major
public
health
concern.
Due
to
complex
pathology
AD,
finding
effective
interventions
has
become
key
focus
research.
Ouabain
(OUA),
cardiac
glycoside,
well-known
for
its
efficacy
in
treating
heart
disease.
Recent
studies
have
also
indicated
potential
therapy,
although
exact
mechanism
action
remains
unclear.
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(2), P. 279 - 279
Published: Jan. 23, 2025
Alzheimer’s
disease
(AD)
is
traditionally
viewed
through
the
lens
of
amyloid
cascade
hypothesis,
implicating
amyloid-beta
and
tau
protein
aggregates
as
main
pathological
culprits.
However,
burgeoning
research
points
to
brain’s
resident
immune
cells,
microglia,
critical
players
in
AD
pathogenesis,
progression,
potential
therapeutic
interventions.
This
review
examines
dynamic
roles
microglia
within
intricate
framework
AD.
We
detail
involvement
these
cells
neuroinflammation,
explaining
how
their
activation
response
fluctuations
may
influence
trajectory.
further
elucidate
complex
relationship
between
pathology.
study
highlights
dual
nature
which
contribute
both
aggregation
clearance
protein.
Moreover,
an
in-depth
analysis
interplay
unveils
significant,
yet
often
overlooked,
impact
this
interaction
on
neurodegeneration
Shifting
from
conventional
approaches,
we
assess
current
treatments
primarily
targeting
introduce
novel
strategies
that
involve
manipulating
microglial
functions.
These
innovative
methods
herald
a
paradigm
shift
management
Finally,
explore
field
precision
diagnosis
pursuit
robust
biomarkers.
underline
more
profound
comprehension
biology
could
enrich
essential
areas,
potentially
paving
way
for
accurate
diagnostic
tools
tailored
treatment
strategies.
In
conclusion,
expands
perspective
pathology
treatment,
drawing
attention
multifaceted
microglia.
As
continue
enhance
our
understanding
microglial-focused
interventions
emerge
promising
frontier
bolster
arsenal
fight
against
Advanced Science,
Journal Year:
2024,
Volume and Issue:
11(31)
Published: June 18, 2024
Abstract
The
microenvironment
mediated
by
the
microglia
(MG)
M1/M2
phenotypic
switch
plays
a
decisive
role
in
neuronal
fate
and
cognitive
function
of
Alzheimer's
disease
(AD).
However,
impact
metabolic
reprogramming
on
microglial
polarization
its
underlying
mechanism
remains
elusive.
This
study
reveals
that
cordycepin
improved
memory
APP/PS1
mice,
as
well
attenuated
damage
triggering
MG‐M2
characterized
increased
OXPHOS
glycolysis,
rather
than
directly
protecting
neurons.
Simultaneously,
partially
alleviates
mitochondrial
induced
inhibitors
further
promoting
transformation
increasing
survival.
Through
confirmation
distribution
mitochondria
via
isolation
followed
HPLC‐MS/MS
techniques,
HKII
PDK2
are
identified
potential
targets
cordycepin.
By
investigating
effects
inhibitors,
through
which
targeted
to
elevate
ECAR
levels
glycolysis
pathway
while
targeting
enhance
OCR
PDH‐mediated
pathway,
thereby
inducing
polarization,
survival
exerting
an
anti‐AD
is
elucidated.
RSC Advances,
Journal Year:
2025,
Volume and Issue:
15(7), P. 5426 - 5451
Published: Jan. 1, 2025
Metal
NPs
cross
BBB
and
release
low
drug
doses
in
a
time-controlled
manner
the
target
site.
AuNPs
IONPs
predominantly
inhibit
neuroinflammation,
while
other
metal
promote
it.
possess
dual
role
modulating
microglia.
Bioconjugate Chemistry,
Journal Year:
2024,
Volume and Issue:
35(11), P. 1687 - 1698
Published: Oct. 8, 2024
Inflammation
within
the
brain
is
a
hallmark
of
wide
range
diseases.
The
complex
role
inflammatory
processes
in
these
conditions
suggests
that
neuroinflammation
could
be
valuable
therapeutic
target.
While
several
promising
anti-inflammatory
agents
have
been
identified,
their
clinical
application
diseases
often
hampered
by
inability
to
cross
blood-brain
barrier
(BBB)
and
reach
therapeutically
effective
concentrations
at
pathological
sites.
This
limitation
highlights
urgent
need
for
BBB-penetrating
drug
delivery
systems
designed
target
inflammation.
review
critically
examines
recent
advances
over
past
five
years
strategies
aimed
mitigating
inflammation
Alzheimer's
disease
ischemic
stroke─two
leading
causes
death
disability
worldwide.
Additionally,
we
address
key
challenges
this
field,
offering
insights
into
future
directions
targeting
treatment
